Ipamorelin + CJC-1295 Stack: Evidence, Mechanism, and Protocol At a glance Drug class / Growth hormone secretagogue (GHRP) + Growth hormone-releasing hormone analogue (GHRH analogue) Ipamorelin receptor target / Ghrelin receptor (GHSR-1a), selective, no cortisol or prolactin spike CJC-1295 receptor target / GHRH receptor (GHRHR) on pituitary somatotrophs Combination mechanism / GHRP + GHRH co-stimulation raises GH pulse amplitude 2-to-10-fold over either agent alone in animal models Typical ipamorelin dose / 100-300 mcg subcutaneous injection, 1-3x daily Typical CJC-1295 (no DAC) dose / 100-300 mcg subcutaneous injection, timed with ipamorelin Typical CJC-1295 with DAC dose / 1,000-2,000 mcg subcutaneous injection, once weekly Primary evidence level / Mechanistic + animal + one Phase II RCT (CJC-1295)
Fairness injection helps to remove dark spots and scars from the skin
BPC-157 (Body Protection Compound): Conhecido como composto de proteo corporal, um pentadecapeptdeo gstrico estudado por sua potente ao na angiognese e no reparo de tecidos moles, como tendes e ligamentos 1
Start the provider review Evidence check Useful peptide pages should separate human data, animal research, mechanistic evidence, and marketing claims
Includes CaloriBurn GP, BioPerine, and Grains of Paradise for amplified thermogenesis and sweat response